Acutaas Chemicals Ltd.
ACUTAAS · NSE · Basic Materials
With a 20% margin of safety, our buy-below price is ₹1,253.27.
Piotroski F-score 5/9 — quality of earnings & balance sheet.
Investability checklist
- ✓ROE above 15%23.5%
- ✓Low debt (D/E < 0.5)0.02x
- ✕Positive free cash flow
- ✓Revenue growth > 10%40%
- ✓Earnings growing106%
- ✓Net margin ≥ 10%26.6%
- ✓Current ratio > 1.53.82
- ✕Below our fair value
- ✕Margin of safety ≥ 20%
- ✓Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 68.11
- ✕Piotroski ≥ 75/9
1-year price
EOD · 2026-06-15Our scores
Key fundamentals
SWOT snapshot
Strengths
- •Strong return on equity (23.5%).
- •Lightly leveraged balance sheet.
- •Healthy profit margin (26.6%).
- •Financially solid — Altman Z 68.11.
Opportunities
- •Earnings growing (106% YoY).
- •Revenue growing (40% YoY).
Threats
- •Rich valuation versus sector peers.
- •Trades ~49% above our estimated fair value.
About Acutaas Chemicals Ltd.
Acutaas Chemicals Limited engages in the research and development, manufacture, and sale of pharmaceutical intermediates in India and internationally. The company offers pharma intermediates for use in regulated and generic active pharmaceutical ingredients for anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson's, antidepressant, and anticoagulant applications. It also provides specialty chemicals for use in battery chemicals, personal care, agroc
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.